Windtree Therapeutics, a Nasdaq-listed biotech firm, has announced plans to purchase up to $700 million in BNB, the fifth-largest cryptocurrency, following its recent all-time high. Initially planning to acquire $200 million worth of BNB, Windtree is raising an additional $520 million through a $500 million equity line of credit and a $20 million stock-purchase agreement. The company aims to leverage partnerships, including one with Kraken for asset custody. CEO Jed Latkin emphasized the importance of securing funds for BNB purchases as part of their financial strategy. BNB, launched by Binance in 2017, has recently seen significant price fluctuations, peaking at $808. Windtree represents a growing trend among publicly traded companies incorporating cryptocurrency into their treasuries to enhance stock value. The firm's stock has risen 162% over the past month despite a minor recent decline, reflecting investor interest in innovative asset strategies in the crypto space.

Source šŸ”—